600285 羚锐制药
已收盘 08-25 15:00:00
资讯
新帖
简况
股市必读：羚锐制药新发布《羚锐制药关于大股东部分股份质押的公告》
证券之星 · 08-24 01:48
股市必读：羚锐制药新发布《羚锐制药关于大股东部分股份质押的公告》
羚锐制药（600285）披露大股东部分股份质押公告，8月21日股价下跌1.26%
证券之星 · 08-21
羚锐制药（600285）披露大股东部分股份质押公告，8月21日股价下跌1.26%
羚锐制药（600285）股东河南羚锐集团有限公司质押430万股，占总股本0.76%
证券之星 · 08-21
羚锐制药（600285）股东河南羚锐集团有限公司质押430万股，占总股本0.76%
每周股票复盘：羚锐制药（600285）股东户数下降2.6%
证券之星 · 08-16
每周股票复盘：羚锐制药（600285）股东户数下降2.6%
羚锐制药（600285）2026年中报简析：营收净利润同比双双增长
证券之星 · 08-13
羚锐制药（600285）2026年中报简析：营收净利润同比双双增长
股市必读：羚锐制药中报 - 第二季度单季净利润同比下降3.42%
证券之星 · 08-13
股市必读：羚锐制药中报 - 第二季度单季净利润同比下降3.42%
8月12日羚锐制药（600285）龙虎榜数据：机构净卖出1961.23万元，北向资金净卖出5685.69万元
证券之星 · 08-12
8月12日羚锐制药（600285）龙虎榜数据：机构净卖出1961.23万元，北向资金净卖出5685.69万元
羚锐制药(600285)6月30日股东户数4.13万户，较上期减少2.6%
证券之星 · 08-12
羚锐制药(600285)6月30日股东户数4.13万户，较上期减少2.6%
羚锐制药上半年实现归属净利润约4.95亿元，同比增长4.36%
北京商报 · 08-11
羚锐制药上半年实现归属净利润约4.95亿元，同比增长4.36%
羚锐制药（600285）披露2026年半年度报告，8月11日股价上涨0.71%
证券之星 · 08-11
羚锐制药（600285）披露2026年半年度报告，8月11日股价上涨0.71%
每周股票复盘：羚锐制药（600285）大股东部分股份解质再质押
证券之星 · 08-09
每周股票复盘：羚锐制药（600285）大股东部分股份解质再质押
羚锐制药（600285）披露大股东部分股份解除质押及再质押公告，8月4日股价下跌1.17%
证券之星 · 08-04
羚锐制药（600285）披露大股东部分股份解除质押及再质押公告，8月4日股价下跌1.17%
羚锐制药（600285）股东河南羚锐集团有限公司质押508.03万股，占总股本0.9%
证券之星 · 08-04
羚锐制药（600285）股东河南羚锐集团有限公司质押508.03万股，占总股本0.9%
每周股票复盘：羚锐制药（600285）获肤痒颗粒上市许可
证券之星 · 06-28
每周股票复盘：羚锐制药（600285）获肤痒颗粒上市许可
羚锐制药新注册《羚锐制药服务商管理系统软件V1.0》项目的软件著作权
证券之星 · 06-25
羚锐制药新注册《羚锐制药服务商管理系统软件V1.0》项目的软件著作权
羚锐制药（600285）披露药品上市许可持有人变更获批公告，6月23日股价上涨0.45%
证券之星 · 06-23
羚锐制药（600285）披露药品上市许可持有人变更获批公告，6月23日股价上涨0.45%
羚锐制药：通络祛痛膏为医保常规目录产品
证券之星 · 06-18
羚锐制药：通络祛痛膏为医保常规目录产品
羚锐制药：公司严格遵守法律法规、公司章程及《羚锐制药未来三年（2024-2026 年度）股东回报规划》相关规定
证券之星 · 06-18
羚锐制药：公司严格遵守法律法规、公司章程及《羚锐制药未来三年（2024-2026 年度）股东回报规划》相关规定
羚锐制药（600285）62.5万股限售股将于6月17日解禁，占总股本0.11%
证券之星 · 06-17
羚锐制药（600285）62.5万股限售股将于6月17日解禁，占总股本0.11%
每周股票复盘：羚锐制药（600285）完成董事会换届并召开业绩说明会
证券之星 · 05-24
每周股票复盘：羚锐制药（600285）完成董事会换届并召开业绩说明会
暂无数据
公司概况
公司名称：
河南羚锐制药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
河南羚锐制药股份有限公司的主营业务是药品的研发、生产及销售。公司的主要产品是橡胶膏剂、片剂、胶囊剂、软膏剂、喷雾剂。
发行价格：
8.30
{"stockData":{"symbol":"600285","market":"SH","secType":"STK","nameCN":"羚锐制药","latestPrice":19.67,"timestamp":1787641201000,"preClose":19.58,"halted":0,"volume":5744786,"delay":0,"changeRate":0.0046,"floatShares":566000000,"shares":567000000,"eps":1.3758,"marketStatus":"已收盘","change":0.09,"latestTime":"08-25 15:00:00","open":19.58,"high":19.75,"low":19.54,"amount":113000000,"amplitude":0.0107,"askPrice":19.67,"askSize":250,"bidPrice":19.66,"bidSize":141,"shortable":0,"etf":0,"ttmEps":1.3758,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787707800000},"marketStatusCode":5,"adr":0,"adjPreClose":19.58,"symbolType":"stock","openAndCloseTimeList":[[1787621400000,1787628600000],[1787634000000,1787641200000]],"highLimit":21.54,"lowLimit":17.62,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":567115486,"isCdr":false,"pbRate":3.45,"roa":"--","peRate":14.297136,"roe":"13.96%","epsLYR":1.34,"committee":0.187007,"marketValue":11155000000,"turnoverRate":0.0101,"status":0,"floatMarketCap":11143000000},"requestUrl":"/m/hq/s/600285/tweets","defaultTab":"tweets","newsList":[{"id":"2661724586","title":"股市必读：羚锐制药新发布《羚锐制药关于大股东部分股份质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2661724586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661724586?lang=zh_cn&edition=full","pubTime":"2026-08-24 01:48","pubTimestamp":1787507295,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，羚锐制药报收于19.54元，下跌1.26%，换手率1.54%，成交量8.72万手，成交额1.7亿元。公司公告汇总：羚锐制药大股东羚锐集团新增质押430万股，累计质押占公司总股本6.56%，用途为经营流动资金周转。公司公告汇总羚锐制药关于大股东部分股份质押的公告河南羚锐集团有限公司持有羚锐制药股份121,817,898股，占公司总股本的21.48%。本次质押4,300,000股后，累计质押股份37,230,300股，占其所持股份比例30.56%，占公司总股本比例6.56%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400000998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","600285","BK0239","BK0070","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661968372","title":"羚锐制药（600285）披露大股东部分股份质押公告，8月21日股价下跌1.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661968372","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661968372?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:09","pubTimestamp":1787321382,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，羚锐制药报收于19.54元，较前一交易日下跌1.26%，最新总市值为110.81亿元。该股当日开盘19.73元，最高19.73元，最低19.35元，成交额达1.7亿元，换手率为1.54%。近日，羚锐制药发布《关于大股东部分股份质押的公告》。公告显示，河南羚锐集团有限公司持有公司股份121,817,898股，占公司总股本的21.48%。本次质押4,300,000股后，累计质押股份37,230,300股，占其所持股份比例30.56%，占公司总股本比例6.56%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100045187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","600285","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661262508","title":"羚锐制药（600285）股东河南羚锐集团有限公司质押430万股，占总股本0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661262508","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661262508?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:41","pubTimestamp":1787308886,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药8月21日公开信息显示，股东河南羚锐集团有限公司向广发银行股份有限公司郑州商城支行合计质押430.0万股，占总股本0.76%。质押详情见下表：截止本公告日，股东河南羚锐集团有限公司已累计质押股份3723.03万股，占其持股总数的30.56%。羚锐制药主营业务：药品的研发、生产和销售。本文数据来源于羚锐制药公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100035097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","BK0070","600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659750811","title":"每周股票复盘：羚锐制药（600285）股东户数下降2.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659750811","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659750811?lang=zh_cn&edition=full","pubTime":"2026-08-16 02:22","pubTimestamp":1786818132,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，羚锐制药报收于19.7元，较上周的22.24元下跌11.42%。股本股东变化近日羚锐制药披露，截至2026年6月30日公司股东户数为4.13万户，较3月31日减少1100.0户，减幅为2.6%。公司公告汇总河南羚锐制药股份有限公司2026年半年度报告摘要显示，公司总资产为5,755,602,398.47元，较上年度末增长2.13%；归属于上市公司股东的净资产为3,231,633,873.95元，较上年度末减少4.97%。公司股票代码为600285，股票简称为羚锐制药，董事会秘书为陶泓宇，证券事务代表为毛改莉。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0077","600285","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659852641","title":"羚锐制药（600285）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2659852641","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659852641?lang=zh_cn&edition=full","pubTime":"2026-08-13 06:02","pubTimestamp":1786572132,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期羚锐制药发布2026年中报。根据财报显示，羚锐制药营收净利润同比双双增长。截至本报告期末，公司营业总收入21.48亿元，同比上升2.32%，归母净利润4.95亿元，同比上升4.36%。持有羚锐制药最多的基金为天弘永利债券A，目前规模为15.11亿元，最新净值1.247，较上一交易日下跌0.1%，近一年上涨1.94%。本文数据来源于羚锐制药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300003404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659690498","title":"股市必读：羚锐制药中报 - 第二季度单季净利润同比下降3.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659690498","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659690498?lang=zh_cn&edition=full","pubTime":"2026-08-13 01:50","pubTimestamp":1786557019,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，羚锐制药报收于20.47元，下跌9.22%，换手率7.74%，成交量43.84万手，成交额9.02亿元。2026年中报显示归母净利润4.95亿元，同比增长4.36%；但第二季度单季归母净利润同比下降3.42%。其中第二季度单季度主营收入10.22亿元，同比下降5.24%；单季度归母净利润2.49亿元，同比下降3.42%；单季度扣非净利润2.37亿元，同比下降0.52%；负债率43.19%，投资收益2180.58万元，财务费用-715.39万元，毛利率78.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300001255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658973299","title":"8月12日羚锐制药（600285）龙虎榜数据：机构净卖出1961.23万元，北向资金净卖出5685.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658973299","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658973299?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:32","pubTimestamp":1786527150,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年8月12日公布的交易公开信息显示，羚锐制药因有价格涨跌幅限制的日收盘价格跌幅偏离值达到7%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年8月12日收盘，羚锐制药报收于20.47元，下跌9.22%，换手率7.74%，成交量43.84万手，成交额9.02亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出1961.23万元，北向资金合计净卖出5685.69万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200029920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","600285","BK0188","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658350973","title":"羚锐制药(600285)6月30日股东户数4.13万户，较上期减少2.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658350973","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658350973?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:23","pubTimestamp":1786526582,"startTime":"0","endTime":"0","summary":"证券之星消息，近日羚锐制药披露，截至2026年6月30日公司股东户数为4.13万户，较3月31日减少1100.0户，减幅为2.6%。在中药行业个股中，羚锐制药股东户数低于行业平均水平，截至6月30日，中药行业平均股东户数为5.38万户。从股价来看，2026年3月31日至2026年6月30日，羚锐制药区间跌幅为8.72%，在此期间股东户数减少1100.0户，减幅为2.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200029286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","600285","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658919336","title":"羚锐制药上半年实现归属净利润约4.95亿元，同比增长4.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919336","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658919336?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:11","pubTimestamp":1786457460,"startTime":"0","endTime":"0","summary":"羚锐制药（600285）发布2026年半年度报告显示，公司上半年实现归属净利润约4.95亿元，同比增长4.36%。半年报显示，2026年上半年，公司实现营业收入约21.48亿元，同比增长2.32%；对应实现归属净利润约4.95亿元，同比增长4.36%。据了解，羚锐制药拥有橡胶膏剂、片剂、胶囊剂、颗粒剂、酊剂、软膏剂、喷雾剂、吸入剂等十余种剂型百余种产品，覆盖骨科、心脑血管、呼吸系统、麻醉镇痛、内分泌、皮肤科、儿科等治疗领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-11/doc-inimyhkh5716402.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-11/doc-inimyhkh5716402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658973916","title":"羚锐制药（600285）披露2026年半年度报告，8月11日股价上涨0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658973916","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658973916?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:07","pubTimestamp":1786457254,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，羚锐制药报收于22.55元，较前一交易日上涨0.71%，最新总市值为127.88亿元。该股当日开盘22.3元，最高22.79元，最低22.28元，成交额达2.73亿元，换手率为2.14%。近日，羚锐制药披露《2026年半年度报告》。报告显示，公司总资产为5,755,602,398.47元，较上年度末增长2.13%；归属于上市公司股东的净资产为3,231,633,873.95元，较上年度末减少4.97%。经营活动产生的现金流量净额为723,340,080.53元，同比增加103.42%。公司未披露利润分配预案，亦无优先股股东、控股股东或实际控制人变更情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100037928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","BK0239","BK0188","600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658737726","title":"每周股票复盘：羚锐制药（600285）大股东部分股份解质再质押","url":"https://stock-news.laohu8.com/highlight/detail?id=2658737726","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658737726?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:04","pubTimestamp":1786212255,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，羚锐制药报收于22.24元，较上周的23.0元下跌3.3%。本周，羚锐制药8月3日盘中最高价报23.65元。公司公告汇总羚锐集团持有羚锐制药股份121,817,898股，占总股本21.48%。本次解除质押9,750,000股，占其所持股份8.00%，占公司总股本1.72%。变动后，羚锐集团累计质押股份32,930,300股，占其持股27.03%，占公司总股本5.81%。羚锐集团及其一致行动人合计持股127,813,609股，累计质押占合计持股的25.76%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0077","600285","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656552867","title":"羚锐制药（600285）披露大股东部分股份解除质押及再质押公告，8月4日股价下跌1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656552867","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656552867?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:18","pubTimestamp":1785853103,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，羚锐制药报收于22.82元，较前一交易日下跌1.17%，最新总市值为129.42亿元。近日，羚锐制药发布《关于大股东部分股份解除质押及再质押的公告》。公告显示，河南羚锐集团有限公司持有河南羚锐制药股份有限公司股份121,817,898股，占公司总股本21.48%。本次解除质押9,750,000股，占其所持股份8.00%，占公司总股本1.72%。本次变动后，羚锐集团累计质押股份32,930,300股，占其持股数量27.03%，占公司总股本5.81%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0070","BK0239","600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656532061","title":"羚锐制药（600285）股东河南羚锐集团有限公司质押508.03万股，占总股本0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656532061","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656532061?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:36","pubTimestamp":1785839785,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药8月4日公开信息显示，股东河南羚锐集团有限公司向交通银行股份有限公司信阳分行、中信银行股份有限公司信阳分行合计质押508.03万股，占总股本0.9%。质押详情见下表：截止本公告日，股东河南羚锐集团有限公司已累计质押股份3293.03万股，占其持股总数的27.03%。羚锐制药主营业务：药品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400033161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","BK0070","BK0077","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646315523","title":"每周股票复盘：羚锐制药（600285）获肤痒颗粒上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2646315523","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646315523?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:14","pubTimestamp":1782587652,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，羚锐制药报收于19.37元，较上周的20.12元下跌3.73%。本周，羚锐制药6月24日盘中最高价报20.39元。6月26日盘中最低价报19.03元，股价触及近一年最低点。羚锐制药当前最新总市值109.85亿元，在中药板块市值排名16/66，在两市A股市值排名1754/5206。肤痒颗粒适用于皮肤瘙痒病、荨麻疹，属OTC甲类、国家医保乙类品种。2025年该药品在零售终端销售额约1.71亿元。公司累计投入约400.63万元。本次变更有利于丰富公司产品线，提升市场竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","600285","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646810416","title":"羚锐制药新注册《羚锐制药服务商管理系统软件V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2646810416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646810416?lang=zh_cn&edition=full","pubTime":"2026-06-25 02:09","pubTimestamp":1782324554,"startTime":"0","endTime":"0","summary":"证券之星消息，近日羚锐制药（600285）新注册了《羚锐制药服务商管理系统软件V1.0》项目的软件著作权。今年以来羚锐制药新注册软件著作权1个。结合公司2025年年报财务数据，2025年公司在研发方面投入了1.69亿元，同比增28.59%。通过天眼查大数据分析，河南羚锐制药股份有限公司共对外投资了14家企业，参与招投标项目26111次；财产线索方面有商标信息402条，专利信息259条，著作权信息48条；此外企业还拥有行政许可650个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500001553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","BK0077","BK0188","BK0239","159180","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645383292","title":"羚锐制药（600285）披露药品上市许可持有人变更获批公告，6月23日股价上涨0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645383292","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645383292?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:20","pubTimestamp":1782224429,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，羚锐制药报收于20.02元，较前一交易日上涨0.45%，最新总市值为113.54亿元。近日，河南羚锐制药股份有限公司收到国家药监局核准签发的肤痒颗粒《药品补充申请批准通知书》，同意该药品上市许可持有人由南京中山制药有限公司变更为河南羚锐制药股份有限公司，药品批准文号不变。肤痒颗粒适用于皮肤瘙痒病、荨麻疹，属OTC甲类、国家医保乙类品种。2025年该药品在零售终端销售额约1.71亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","BK0188","BK0070","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644403709","title":"羚锐制药：通络祛痛膏为医保常规目录产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2644403709","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644403709?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:12","pubTimestamp":1781773965,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药(600285)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司拳头产品通络祛痛膏是基药和医保双目录产品，因为是独家产品，未有集采。那么，该药医保支付价格是如何确定的？是一成不变还是要定期协商谈判？羚锐制药回复：尊敬的投资者，您好！通络祛痛膏为医保常规目录产品，不属于国家谈判药品和国家集采中选药品。感谢您对公司的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800029917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","BK0070","600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644709491","title":"羚锐制药：公司严格遵守法律法规、公司章程及《羚锐制药未来三年（2024-2026 年度）股东回报规划》相关规定","url":"https://stock-news.laohu8.com/highlight/detail?id=2644709491","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644709491?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:09","pubTimestamp":1781773750,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，看到公司2026年一季度现金只有4.5亿。同时公司短期借款2.7亿。公司财务情况请参考公告的公司定期财务报告。公司严格遵守法律法规、公司章程及《羚锐制药未来三年股东回报规划》相关规定，并综合考虑所处行业特点、发展阶段、自身经营模式及盈利水平等因素制定分红方案。感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800029782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0188","600285","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644279626","title":"羚锐制药（600285）62.5万股限售股将于6月17日解禁，占总股本0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644279626","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644279626?lang=zh_cn&edition=full","pubTime":"2026-06-17 08:12","pubTimestamp":1781655179,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，羚锐制药于6月17日将有62.5万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.11%。本次解禁后，公司还有62.5万股限售股份，占总股本0.11%。羚锐制药主营业务：药品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700006786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","BK0070","600285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637376376","title":"每周股票复盘：羚锐制药（600285）完成董事会换届并召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2637376376","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637376376?lang=zh_cn&edition=full","pubTime":"2026-05-24 04:36","pubTimestamp":1779568574,"startTime":"0","endTime":"0","summary":"河南羚锐制药股份有限公司于2026年5月20日召开职工代表大会，选举陈燕女士为公司第十届董事会职工代表董事。河南羚锐制药股份有限公司于2026年5月20日在河南省新县召开2025年年度股东会，会议由董事会召集，董事长熊伟主持，采用现场与网络投票结合方式召开。河南羚锐制药股份有限公司将于2026年5月29日15:00-16:00通过上证路演中心召开2025年年度暨2026年第一季度业绩说明会，介绍公司经营成果和财务状况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","BK0077","BK0188","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787684773615,"stockEarnings":[{"period":"1week","weight":-0.003},{"period":"1month","weight":-0.1022},{"period":"3month","weight":-0.0419},{"period":"6month","weight":-0.0383},{"period":"1year","weight":-0.1257},{"period":"ytd","weight":-0.0003}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":0.0197},{"period":"3month","weight":-0.0499},{"period":"6month","weight":-0.062},{"period":"1year","weight":0.0015},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"河南羚锐制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41265人(较上一季度减少2.60%)","perCapita":"13728股","listingDate":"2000-10-18","address":"河南省信阳市新县将军路666号","registeredCapital":"56711万元","survey":" 河南羚锐制药股份有限公司的主营业务是药品的研发、生产及销售。公司的主要产品是橡胶膏剂、片剂、胶囊剂、软膏剂、喷雾剂。","listedPrice":8.3},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供羚锐制药(600285)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"羚锐制药,600285,羚锐制药股票,羚锐制药股票老虎,羚锐制药股票老虎国际,羚锐制药行情,羚锐制药股票行情,羚锐制药股价,羚锐制药股市,羚锐制药股票价格,羚锐制药股票交易,羚锐制药股票购买,羚锐制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供羚锐制药(600285)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}